<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732290</url>
  </required_header>
  <id_info>
    <org_study_id>0801068</org_study_id>
    <secondary_id>2008-004395-46</secondary_id>
    <nct_id>NCT00732290</nct_id>
  </id_info>
  <brief_title>Investigation of Drug-drug Interaction Between Clopidogrel and Fluoxetine</brief_title>
  <acronym>PLATINE</acronym>
  <official_title>Investigation of Drug-drug Interaction Between Clopidogrel and Fluoxetine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel is a platelet aggregation inhibitor witch prevents thrombotic events in patients
      with atherosclerotic vascular disease. To date, 4 to 30 % of patients are considered as poor,
      low or non-responder to this therapeutic. However, drug-drug interactions may lead to
      decrease the clopidogrel responsiveness. Many arguments are in support to a drug-drug
      interaction between clopidogrel and fluoxetine (selective serotonin reuptake inhibitor). On
      the pharmacokinetic level, fluoxetine inhibits the cytochroms involved in the production of
      clopidogrel active metabolite. On the pharmacodynamic level fluoxetine could increase the
      risk of hemorrhage by inhibiting the serotonin platelet reuptake and thus enhance the
      antiplatelet effect of clopidogrel.

      The purpose of this study is to investigate the influence of fluoxetine on pharmacokinetic
      and pharmacodynamic of clopidogrel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet aggregation inhibition measured by optical aggregometry in presence of adenosine diphosphate (ADP) 20 μmol/L and 5 μmol/L.</measure>
    <time_frame>Before first fluoxetin taking, during clopidogrel taking</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of phosphorylated VASP (vasodilator- stimulated phosphoprotein), a good index of P2Y12 activity (platelet receptor of clopidogrel) and P-selectin by flow cytometry.</measure>
    <time_frame>Before first Fluoxetine taking and during Clopidogrel taking</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of clopidogrel and its metabolites in plasma by LC/MS-MS method</measure>
    <time_frame>During clopidogrel taking</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel then fluoxetine+clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fluoxetine+clopidogrel then clopidogrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel then fluoxetine+clopidogrel</intervention_name>
    <description>D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine+clopidogrel then clopidogrel</intervention_name>
    <description>D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed an informed consent

          -  Body mass: 60 to 85 Kg

          -  Platelet count: 180 to 350 G/L

          -  % platelet aggregation &gt; 70%

          -  Subjects are to be in good health as determined by a medical history, physical
             examination including vital signs, and clinical laboratory test results including
             liver function, renal and full blood count

        Exclusion Criteria:

          -  Subject with an history of seizure disorder

          -  Subject with a known allergy fluoxetine or clopidogrel

          -  Cigarette smoking

          -  Subject with a history of hemorrhagic disease

          -  Peptic ulcer

          -  Psychiatric disorders

          -  Participation in another clinical or device trial within the three previous months

          -  Subject who is currently taking medications

          -  Subject who is currently taking medications for depression

          -  Subject with an history of depression (MADRS score &lt; 15)

          -  Hepatic insufficiency
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre GARNIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Medecin et Therapeutique, Unite de Recherche Clinique Groupe de Recherche sur la Thrombose (EA3065)</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2008</study_first_submitted>
  <study_first_submitted_qc>August 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <last_update_submitted>March 22, 2013</last_update_submitted>
  <last_update_submitted_qc>March 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteer</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>Polymorphism, Genetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

